Detailed Information on Publication Record
2015
Atypical nuclear localization of CD133 plasma membrane glycoprotein in rhabdomyosarcoma cell lines
ŇUŇUKOVÁ, Alena, Jakub NERADIL, Jan ŠKODA, Josef JAROŠ, Aleš HAMPL et. al.Basic information
Original name
Atypical nuclear localization of CD133 plasma membrane glycoprotein in rhabdomyosarcoma cell lines
Authors
ŇUŇUKOVÁ, Alena (703 Slovakia, belonging to the institution), Jakub NERADIL (203 Czech Republic, belonging to the institution), Jan ŠKODA (203 Czech Republic, belonging to the institution), Josef JAROŠ (203 Czech Republic, belonging to the institution), Aleš HAMPL (203 Czech Republic, belonging to the institution), Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution) and Renata VESELSKÁ (203 Czech Republic, guarantor, belonging to the institution)
Edition
International Journal of Molecular Medicine, Athens, Spandidos Publications Ltd, 2015, 1107-3756
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
Genetics and molecular biology
Country of publisher
Greece
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.348
RIV identification code
RIV/00216224:14310/15:00087462
Organization unit
Faculty of Science
UT WoS
000358134900007
Keywords in English
CD133; prominin-1; rhabdomyosarcoma; cell nuclei; immunodetection
Tags
International impact, Reviewed
Změněno: 25/11/2015 20:58, prof. RNDr. Renata Veselská, Ph.D., M.Sc.
Abstract
V originále
CD133 (also known as prominin-1) is a cell surface glycoprotein that is widely used for the identification of stem cells. Furthermore, its glycosylated epitope, AC133, has recently been discussed as a marker of cancer stem cells in various human malignancies. During our recent experiments on rhabdomyosarcomas (RMS), we unexpectedly identified an atypical nuclear localization of CD133 in a relatively stable subset of cells in five RMS cell lines established in our laboratory. To the best of our knowledge, this atypical localization of CD133 has not yet been proven or analyzed in detail in cancer cells. In the present study, we verified the nuclear localization of CD133 in RMS cells using three independent anti-CD133 antibodies, including both rabbit polyclonal and mouse monoclonal antibodies. Indirect immunofluorescence and confocal microscopy followed by software cross-section analysis, transmission electron microscopy and cell fractionation with immunoblotting were also employed, and all the results undeniably confirmed the presence of CD133 in the nuclei of stable minor subpopulations of all five RMS cell lines. The proportion of cells showing an exclusive nuclear localization of CD133 ranged from 3.4 to 7.5%, with only minor differences observed among the individual anti-CD133 antibodies. Although the role of CD133 in the cell nucleus remains unclear, these results clearly indicate that this atypical nuclear localization of CD133 in a minor subpopulation of cancer cells is a common phenomenon in RMS cell lines.
Links
| NT13443, research and development project |
|